This article was initially published on, written by George Macdonald

Brean Capital Reiterates a Hold Rating on Zimmer

In a report released yesterday, Jason Wittes from Brean Capital reiterated a Holdrating on Zimmer (NYSE: ZBH). The company’s shares closed yesterday at $108.54.

Wittes said, “For 2Q15, we are projecting revenues of $1,172 million and EPS of $1.58 per share versus consensus of $1,150 million and $1.55 per share. We note that we downgraded the stock to a Hold from a Buy on June 25, 2015, as we believe uncertainty on 2016 will keep the stock range bound—we don’t expect any greater clarity this quarter. Note that these are Zimmer standalone estimates, but actual numbers include Biomet impact from the merger, which closed on June 24th.”

Zimmer has an analyst consensus of Moderate Buy, with a price target consensus of $135.67.

The company has a one year high of $121.38 and a one year low of $93.99. Currently, Zimmer has an average volume of 1.24M.

Financial bloggers on sites such as, and others, seem to have a Positive view on ZBH. When evaluating the opinions of financial bloggers over the last 3 months, 66% of bloggers have indicated a Bullish sentiment, while 34% have indicated a Bearish sentiment. The average blogger Bullish sentiment in the Healthcare sector is 67% which is slightly more positive than the blogger sentiment of ZBH.

Unlike Brean Capital`s latest rating, based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ZBH in relation to earlier this year. Earlier this month, PRIVATE EQUITY PARTNERS 2005 DIRECT LP, a major Shareholder at ZBH bought 7,532,650 shares.

According to, Wittes is a 4-star analyst with an average return of 9.6%and a 73.3% success rate. Wittes covers the Healthcare sector, focusing on stocks such as Varian Medical Systems, Smith & Nephew Snats, and Wright Medical Group.

Zimmer Biomet Holdings Incis engaged in designing, manufacturing & marketing orthopaedic reconstructive products; sports medicine, biologics, extremities & trauma products; spine, bone healing, craniomaxillofacial & thoracic products & dental implants..